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Abstract
Background: Lower extremity artery disease (LE-PAD) is one of the most common manifestations of
atherosclerosis, particularly in elderly patients, and it is related to a high cardiovascular risk.
Description: It is well established that statin therapy is characterized by crucial benefits on cardiovascular system
by limiting atherosclerotic progression and reducing cardiovascular events and mortality. A growing body of
evidence support efficacy of statins in LE-PAD due to the ability of both reducing cardiovascular risk and improving
walking distance and, hence, quality of life. Consequently, statin therapy should be considered in all LE-PAD
patients and new LDL-cholesterol targets should be reached.
Conclusions: Our opinion is that statin therapy remains still underutilized or with inadequate dosage, so therapy
of LE-PAD patients should be improved to obtain all the demonstrated benefits of statins.
Background
Lower extremity artery disease (LE-PAD) is one of the
most common manifestations of atherosclerosis and its
frequency is strongly related to age: uncommon before
50 years, rising steeply at older ages. A substantial percen-
tage of patients with chronic coronary artery disease
(CAD) have associated cerebrovascular disease, LE-PAD,
or both. Consequently, LE-PAD represents a marker of
diffuse atherosclerosis implying a high cardiovascular risk
[1-3] and, in symptomatic patients, it is also an important
cause of disability. Secondary prevention of cardiovascular
risk factors is mandatory in all LE-PAD patients to
improve cardiovascular prognosis, while revascularization
should be restricted to symptomatic patients. In order to
improve symptoms and walking distance capacity conser-
vative or invasive approaches (endovascular or surgical
revascularization) can be undertaken. The conservative
strategy is effective and based on pharmacologic agents
(anti-platelet, lipid-lowering, antihypertensive; cilostazol;
naftidrofuryl; pentoxifylline; carnitine; buflomedil) and
exercise therapy, whose beneficial effects on LE-PAD and
the cardiovascular system are well established [1,4]. While
revascularization is recommended in patients with critical
limb ischemia (CLI), the evidence of any long-term benefit
of endovascular treatment over supervised exercise and
best medical treatment is inconclusive, particularly in
patients with mild to moderate claudication. However,
advances in the endovascular treatment of LE-PAD have
prompted many physicians to consider more liberal
indications for percutaneous intervention. Endovascular
revascularization is also indicated in patients with lifestyle-
limiting claudication when clinical features suggest a
reasonable likelihood of symptomatic improvement and
there has been an inadequate response to conservative
therapy. In aorto-iliac lesions, endovascular revasculariza-
tion can be considered without initial extensive conserva-
tive treatment. Endovascular revascularization for the
treatment of patients with LE-PAD has developed rapidly
during the past decade, and a great number of patients
can now be offered the less invasive treatment option.
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Despite numerous advantages, the major drawback of
endovascular interventions, compared with surgery, is the
lower long-term patency, mainly due to restenosis [5-9].
However, an increasing number of centres favour an endo-
vascular approach first, due to reduced morbidity and
mortality, compared with vascular surgery, while preser-
ving the surgical option in case of failure.
Methods
Pleiotropic effects and cardiovascular benefits of statin
therapy are well-established [10-14], in particular their
beneficial effects on atherosclerosis (reduction of choles-
terol levels, inhibition of inflammation and plaque stabili-
zation). In addition, statins reduce the risk of mortality,
cardiovascular events, and stroke in patients with LE-PAD
with and without coronary artery disease (CAD) [10,11].
According to these considerations, LE-PAD treatment
has two main objectives: 1) to reduce cardiovascular risk,
2) to improve walking distance and, hence, quality of life.
A large body of evidence demonstrates that statins exert
positive effects on both. In a retrospective trial, Aronow
and Ahn [15] observed a significant reduction of coronary
events in 318 LE-PAD patients treated with statins related
to 342 untreated patients. Shillinger et al. [16], in a pro-
spective non-randomized trial, described that LE-PAD
patients treated with statins had a halved risk of death and
myocardial infarction. This latter result was considered
predominantly due to the anti-inflammatory effects of
statins, since patients with low levels of C-Reactive Protein
(CRP) did not evidence a significant benefit from this ther-
apy. Feringa et al. [17], in a 8-years perspective trial,
demonstrated that the use of statins was associated to a
reduced incidence of death (HR = 0,46, 95% CI 0,58-0,80,
p<0.001). In the REGRESS trial [18], designed in order to
test the effects of two-year-treatment with pravastatin on
coronary arteries, it was demonstrated also a significant
reduction of carotid and femoral intima-media thickness
(assessed by echo-color-doppler) and a significant reduc-
tion of cardiovascular events compared to placebo. In the
Heart Protection Study [10], a double blind randomized
study, 6748 participants had PAD; at 5-year-follow-up,
simvastatin-treated patients showed a significant 19% rela-
tive reduction and a 6.3% absolute reduction in major car-
diovascular events related to placebo-treated patients,
independently of age, gender, or serum lipid levels.
Beyond the evidence that statins improve the cardiovas-
cular prognosis of patients with LE-PAD, several studies
reported preliminary positive effects of statins on intermit-
tent claudication [19,20]. The increase in maximal walking
distance reported varied, on average, from 50 to 100 m. In
one meta-analysis, the pooled effect estimate showed a
relevant increase in maximal walking distance of 163 m16.
In the 4S trial [21], simvastatin reduced incidence or
worsening of claudication in hypercholesterolemic
patients. McDermott et al. [22] described a better walking
performance in LE-PAD patients treated with statins,
although these benefits were attenuated when considered
CRP levels. The beneficial effects of simvastatin on walk-
ing distance in LE-PAD patients were also shown by
Aronow et al. and Mondillo et al. [23]. Mohler et al. [24]
demonstrated that atorvastatin prolongs walking distance
without claudication and improves quality of life. Based on
this growing evidence, recent European and American
guidelines consider LE-PAD at the same level of CAD,
recommending the use of statins in all LE-PAD patients
in the absence of contraindication. Particularly, serum
LDL cholesterol should be reduced to <2.5 mmol/L
(<100 mg/dL), and optimally to <1.8 mmol/L (<70 mg/dL),
or ≥50% LDL cholesterol reduction when the target level
cannot be reached [1].
Conclusions
Our opinion is that statin therapy remains still underuti-
lized or with inadequate dosage, so therapy of LE-PAD
patients should be improved to obtain all the demon-
strated benefits of statins.
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